NasdaqGM:CRSPBiotechs
The Bull Case For CRISPR Therapeutics (CRSP) Could Change Following CASGEVY Uptake And New Capital Raise – Learn Why
CRISPR Therapeutics AG recently reported first-quarter 2026 results, showing revenue of US$1.46 million and a net loss of US$122.93 million, while highlighting ongoing commercial uptake of its gene-edited therapy CASGEVY and progress across multiple gene editing programs.
The company also strengthened its balance sheet with US$600 million in Convertible Senior Notes and plans to showcase its pipeline and commercialization updates at the upcoming Bank of America Securities 2026 Global...